Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
17/26/17	0.2690 €	+1.89%	13,427
16/26/16	0.2640 €	0.00%	10,234
15/26/15	0.2640 €	+0.76%	17,645
12/26/12	0.2620 €	-7.09%	8,159
11/26/11	0.2820 €	-0.70%	12,324

Real-time Euronext Bruxelles

More quotes

Income Statement and Estimates

More financial data

Market Closed - Euronext Bruxelles Other stock markets 09:25:00 17/06/2026 pm IST			5-day change	1st Jan Change
0.2690 ^EUR	+1.89%		-5.28%	+58.24%

15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	1.18Cr 1.37Cr 1.09Cr 1.02Cr 1.92Cr 129.64Cr 1.94Cr 13Cr 5.01Cr 63Cr 5.15Cr 5.04Cr 220.01Cr	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	1.01Cr 1.17Cr 93.09L 87.4L 1.64Cr 110.9Cr 1.66Cr 11Cr 4.29Cr 54Cr 4.4Cr 4.31Cr 188.21Cr	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	30.7%	Yield 2024 *	-	Yield 2025	-

15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/25/29	Celyad Oncology announces research facility divestiture	RE
29/25/29	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/25/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/25/29	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/25/28	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/25/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/25/24	Celyad Oncology Announces Strategic Review	CI
02/25/02	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
18/25/18	Celyad: share price soars on encouraging data

28/22/28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/22/11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/21/06	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/21/26	CELYAD ONCOLOGY : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/20/08	CELYAD ONCOLOGY : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

Celyad Oncology SA Share Price

Stocks

CYAD

BE0974260896

Biotechnology & Medical Research

Valuation: Celyad Oncology SA

Chart: Celyad Oncology SA

Latest news : Celyad Oncology SA

Analysts' recommendations: Celyad Oncology SA

Press Releases: Celyad Oncology SA

News in other languages: Celyad Oncology SA

Quotes and Performance

Course Extremes

Managers and Directors: Celyad Oncology SA

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

20/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/25/29	Celyad Oncology : Announces Research Facility Divestiture	PU
12/25/12	Celyad Oncology SA - Publication of a transparency notification received from Fortress Investment Group LLC	AQ
11/25/11	Celyad Oncology SA: Publication of a Transparency Notification Received From Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)	PU

20/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR
17/04	Celyad Oncology : Statutory Annual Accounts 2025 FR
17/04	Celyad Oncology : Shareholder Proxy Legal Entities FR / EN
17/04	Celyad Oncology : Shareholder Proxy Natural Persons FR / EN

1 day	+1.89%
1 week	-5.28%
Current month	-7.24%
1 month	-1.10%
3 months	-13.50%
6 months	+41.58%
Current year	+58.24%

1 week	0.25	0.29
1 month	0.25	0.31
Current year	0.17	0.65
1 year	0.16	0.65
3 years	0.16	1.28
5 years	0.16	4.62
10 years	0.16	56.48

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD ONCOLOGY SA	+1.89%	-5.28%	-35.02%	-47.25%	1.37Cr
LONZA GROUP AG	-0.22%	-1.14%	-11.88%	-10.15%	4.35TCr
REVOLUTION MEDICINES, INC.	+2.68%	+11.14%	+309.43%	+524.03%	3.33TCr
BEONE MEDICINES AG	+0.15%	+0.65%	+4.42%	+38.50%	2.93TCr
IQVIA HOLDINGS INC.	-2.88%	-4.95%	+12.36%	-19.44%	2.99TCr
CELLTRION, INC.	+0.06%	+2.71%	+13.31%	+21.11%	2.54TCr
ASCENDIS PHARMA A/S	+0.46%	+10.46%	-	-	1.44TCr
MEDPACE HOLDINGS, INC.	+0.86%	-0.31%	+55.84%	+106.08%	1.32TCr
EUROFINS SCIENTIFIC SE	-0.29%	-4.40%	+3.13%	+4.23%	1.27TCr
IONIS PHARMACEUTICALS, INC.	+2.60%	+2.33%	+107.55%	+82.69%	1.21TCr
Average	+0.50%	+0.76%	+51.02%	+77.76%	2.14TCr
Weighted average by Cap.	+0.15%	+0.72%	+63.65%	+102.97%

	2024	2025
Net sales	2L 2L 2L 2L 3L 2.04Cr 3L 20.24L 8L 99.93L 8L 8L 3.46Cr	21T 24.37T 19.34T 18.16T 34.09T 23.04L 34.45T 2L 89.02T 11.28L 91.45T 89.51T 39.1L
Net income	-58.24L -67.58L -53.63L -50.35L -94.54L -64Cr -95.54L -6.34Cr -2.47Cr -31Cr -2.54Cr -2.48Cr -108.43Cr	8L 10L 8L 7L 13.47L 9.11Cr 13.62L 90.31L 35.18L 4.46Cr 36.14L 35.38L 15Cr
Net Debt	-32.95L -38.23L -30.34L -28.49L -53.49L -36Cr -54.05L -3.59Cr -1.4Cr -18Cr -1.43Cr -1.4Cr -61Cr	-17.08L -19.82L -15.73L -14.77L -27.73L -19Cr -28.02L -1.86Cr -72.4L -9.18Cr -74.38L -72.8L -32Cr